Public Health Events Emergency Management Supervision Strategy Considering New Media and Citizen Participation

Public health events endanger the citizen health, economic development, social stability and national security seriously. Emergency management requires the joint participation of multiple parties. Therefore, we construct an evolutionary game model involving government department, pharmaceutical enterprises, citizens and new media, analyze the evolutionary stability, solve the stable equilibrium points using the Lyapunov first method and conduct the simulation analysis with Matlab 2020b. The results show that, firstly, the greater the probability of citizens making true evaluation, the more inclined the government department is to strictly implement the emergency management system, and when true evaluation causes the government department to bear more punishment, the probability that the government department doesn't strictly implement is smaller; secondly, when the probability of citizens making true evaluation decreases, new media are more inclined to report after verification, and when new media lose more pageview value or should be punished more for reporting without verification, the probability that they report without verification is smaller; thirdly, the greater the probability of citizens making false evaluation, the less enthusiasm of pharmaceutical enterprises to participate in emergency management, which indicates that false evaluation is detrimental to prompt pharmaceutical enterprises to participate; what's more, the greater the probability of new media reporting after verification, the greater the probability of pharmaceutical enterprises actively participating, which shows that new media's verification to citizens' evaluation is beneficial to emergency management. So, this paper provides suggestions for the emergency management and supervision.

The Use of Digital Technologies for the Purpose of Improving Methodological Approaches to the Creation of a Pharmaceutical Quality System at Enterprises for the Production of Medicines

Introduction. The article is devoted to the aspects of improving methodological approaches to the creation of a pharmaceutical quality system (PQS) at enterprises for the production of medicines, taking into account the possibility of using tools and means of digitalization. The relevance of the study is associated with the enduring importance of comprehensive high quality assurance in the development, production and release of medicines into circulation. The implementation of PQS requires numerous transformations of management and production processes, which can be facilitated by tools and elements of digitalization.Aim. To consider the potential and specific areas of application of digital technologies to improve the methodology and practice of developing and implementing PQS.Materials and methods. The state in the subject area was assessed on the basis of the results of economic and statistical analysis and forecasting of the implementation of PQS at Russian pharmaceutical enterprises that have positive and comparatively long experience in this area: the companies LLC "OZON" and JSC "AKRIKHIN". The assessment was carried out by calculating the integral indicator of the effectiveness of the functioning of PQS, which is a set of weighted key performance indicators (KPI) for quality.Results and discussion. The importance of the introduction of PQS for the development of pharmaceutical enterprises and the presence of numerous difficulties in the implementation of PQS, which necessitates the improvement of methodological approaches in the subject area, are stated. It has been proven that even at those enterprises where PQS has been introduced with varying degrees of success, the use of digitalization tools would contribute to a faster, more systematic and high-quality implementation of PQS. Among the key areas of application of digital tools, the authors propose monitoring of quality indicators (using neural network cards) and the use of blockchain platforms and smart contracts to register the release of drugs of appropriate quality.Conclusion. Digital tools contribute to complex improvement in many areas of socio-economic activity. Their active use at pharmaceutical enterprises is intended to contribute to ensuring the proper implementation and uninterrupted functioning of pharmaceutical quality systems, through constant monitoring of the quality of manufactured products and registration of manufactured batches in high-precision information storage systems.

Impact of Monetary Policy Uncertainty on R&D Investment Smoothing Behavior of Pharmaceutical Manufacturing Enterprises: Empirical Research Based on a Threshold Regression Model

R&D investment is the source of technological innovation of pharmaceutical enterprises, but it will be restricted by the funding level, especially in the context of major public health emergencies occurring more frequently, therefore exploring the impact of monetary policy uncertainty on the R&D investment smoothing behavior of pharmaceutical manufacturing enterprises has important theoretical and practical value. Based on the relevant data of Chinese pharmaceutical manufacturing enterprises from 2012 to 2018, this paper studies the impact of monetary policy uncertainty on R&D investment smoothing behavior of pharmaceutical enterprises, and investigates whether there is a threshold effect. First, our results demonstrate that the empirical test results of this article support the hypothesis of R&D investment smoothing behavior of pharmaceutical manufacturing enterprises. Second, there is a negative correlation between monetary policy uncertainty and R&D investment smoothing behavior, and the shorter the period is, the higher the financing constraints of pharmaceutical enterprises are, and the more obvious the negative correlation is. Third, financing constraints have a single threshold effect on the R&D investment smoothing behavior of pharmaceutical manufacturing enterprises, with a threshold of −13.7693. Moreover, this conclusion can better promote the virtuous circle of the real economy of financial and pharmaceutical manufacturing enterprises. It is recommended that pharmaceutical manufacturing enterprises establish and improve the enterprise R&D reserve system, reduce the risk of R&D investment, play the role of R&D smoothing, and realize the sustainable development of enterprise R&D.

The Financial Impact of Patents on SMEs in China: Empirical Evidence from Pharmaceutical Sector

With the disruptive technology innovation time arrival, small and medium-sized enterprises (SMEs) have been the motor of innovation and played an increasingly major role in national economic development. As the shift towards an ‘open innovation’ paradigm, awareness of intellectual property rights has increased, and patents have been an important tool for Chinese pharmaceutical enterprises. Considering its mass production of low-level generic drugs, there are still many arguments about its lack of innovation. This article aims to identify if and how patents, as essential indicators of innovation, generate financial performance measured by SMEs in the pharmaceutical sectors. Patent data are a vital source of competitive intelligence. A positive association was found between annually added patents and gross sales. Many other patent indicators, such as the number of forward citations and patent transfer, were statistically significant. Moreover, the results suggested that there was a one-year lag between patent publication and financial performance. A series of patent quantity and quality indicators have shown significant effects on the financial performance of Chinese pharmaceutical enterprises. These patents generate a positive financial impact, which builds up a solid basis for keeping sustainable innovation capability in the Chinese drug industry.

On Chinese-English Translation Strategies of Biopharmaceutical Corporate Profiles Guided by Adaptation Theory

With the closer economic ties between countries and the spread of epidemics such as COVID-19, Chinese pharmaceutical enterprises have a potential international market. The quality of the English translation of pharmaceutical company profiles is of great significance to the development of international market and human health. Compared with 8 Chinese and 8 English pharmaceutical company profiles, there are significant different focuses. Besides the basic information, Chinese pharmaceutical company profiles stress the history and awards of the companies, while English pharmaceutical company profiles are centered on the effective information. The existing C-E translation problems lie in word-for-word translation, lack of logic between sentences or text and redundancy. Guided by adaptation theory, the following conclusions are drawn: on syntax level, when translating, the translator should apply the methods of creative translation, clarify the logical relationship between clauses, adjust the word order of sentences and appropriately add logical conjunctions. On discourse level, the translator can use creative translation— recompose the information of the profiles. Besides, we should emphasize the company’s care for life and health. Only in this way can contextual relations and linguistic structure be adapted. I hope it will be helpful to the English translation of the profiles of Chinese pharmaceutical enterprises.

Characteristics of Volatile Organic Compound Leaks from Equipment Components: A Study of the Pharmaceutical Industry in China

Leak detection and repair (LDAR) plays an important role in controlling the fugitive emission of volatile organic compound (VOC) from chemical enterprises. At present, many policies and standards issued in China have set clear requirements for implementing LDAR in the pharmaceutical industry. In this study, the LDAR work of nine typical pharmaceutical enterprises was selected for analysis to allow investigation of the characteristics of VOC emissions from leaking equipment components. Some suggestions for controlling VOC are proposed to provide a reference for managing the fugitive emissions of VOC from pharmaceutical enterprises. The results showed that the number of equipment components used by the pharmaceutical enterprises ranged from several thousand to more than 20,000, which is lower than that in oil refining and coal chemical enterprises. The predominant leaky component was the flange, which accounted for 56.31% of the total, followed by connectors (21.51%) and valves (18.53%). Light liquid medium components accounted for the largest proportion of equipment (52.83%) on average, followed by gas medium components (45.52%, on average). Heavy liquid medium components, which are rarely used in pharmaceuticals, accounted for only 1.65%. The average leak ratio of the components in the pharmaceutical industry was approximately 0.99%. The leak ratio of the open-ended line was much higher than that of other types of components, reaching an average of 5.00%, while that value was only 0.92% for the flange, despite the numbers and proportion of them that were in use. The total annual VOC leakage from the nine pharmaceutical enterprises studied in this work was 20.11 tons, with an average of 2.23 tons per enterprise and an average of 0.22 kg/a per equipment component. Flanges, connectors, and valves were the top three contributors to leakage, generating 39.17%, 38.72%, and 16.79% of the total, respectively, and a total proportion of 94.68%. Although the number of pumps accounted for only 0.15% of the components, it generated 1.94% of the leakage. In terms of different production processes, the greatest unit product leakage came from the bulk production of chemicals used for pharmaceuticals, reaching 0.085 t/a. The production from traditional Chinese medicine enterprises was the lowest (0.011 t/a), which was only 12.80% of the leakage from the bulk production of chemicals for drugs. The leakage of VOC from the equipment components in the nine enterprises was reduced, to varying degrees, using LDAR. The overall reduction ratio was between 23.55% and 67.72%, with an average of 44.02%. The reduction in leakage was relatively significant after the implementation of LDAR; however, there is still room for improvement. Pharmaceutical enterprises should improve their implementation of LDAR and reduce VOC leakage by reducing the number of inaccessible components used and increasing the repair ratio of leaky components. Controlling the source of component leakage, which should be emphasized, can be realized by cutting down the number of components used, adopting low-leakage equipment, and putting anti-leakage measures in place.